Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
February 15, 2023
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
November 21, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
October 31, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress
September 10, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
September 06, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Bridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia Areata
September 01, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress
August 22, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement
August 22, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata
August 01, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022
July 29, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference
June 09, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology
June 07, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants
June 06, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Announces Pricing of Public Offering
June 01, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 31, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
May 23, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
May 05, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022
April 28, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022
February 24, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
January 04, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
January 03, 2022
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences
November 11, 2021
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
November 09, 2021
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Announces $65 Million Financing
November 04, 2021
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals to Report Third Quarter 2021 Results on November 9, 2021
November 02, 2021
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
October 25, 2021
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
September 03, 2021
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Landmarks and Bridges Will Illuminate Blue Throughout the Month of September for Alopecia Areata Awareness Month
August 31, 2021
From
Concert Pharmaceuticals, Inc.
Via
Business Wire
Tickers
CNCE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.